Patient Recruitment for Lung Cancer Clinical Trial

Patient Recruitment for Lung Cancer Clinical Trial

The Second Respiratory Department of Gansu Wuwei Cancer Hospital is currently conducting three clinical studies. These studies have been approved by the National Medical Products Administration and have also received approval from the Ethics Committee of Gansu Wuwei Cancer Hospital.

Project 1: A Phase II clinical study evaluating the efficacy and safety of HLX43 (a PD-L1-targeting ADC) in combination with serplulimab (an anti-PD-1 humanized monoclonal antibody injection) in advanced lung cancer.

Selection criteria:

1. Age ≥18 years and ≤75 years at the time of signing the ICF, regardless of gender.  

2. Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-small cell lung cancer that is unsuitable for curative therapy, with previously confirmed negative EGFR and ALK gene alterations based on tissue sample testing.  

3. Histologically or cytologically confirmed small cell lung cancer (SCLC) that is unsuitable for curative therapy.  

4. Subjects must meet the following prior treatment requirements:  

  (1) Have received platinum-based chemotherapy combined with anti-PD-1/L1 monoclonal or biclonal antibodies as prior first-line treatment, with a maximum of two prior lines of therapy.  

  (2) Have received sequential treatment with platinum-based chemotherapy and anti-PD-1/L1 monoclonal or biclonal antibodies (in any order), with a maximum of three prior lines of therapy.

Project 2: A Randomized, Controlled, Open-label Phase III Clinical Study of JMT101 Combined with Osimertinib versus Osimertinib as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations.

Selection criteria:

1. Age ≥ 18 years, regardless of gender.
2. Newly diagnosed patients with locally advanced (clinical stage IIIB or IIIC) or metastatic non-squamous non-small cell lung cancer, who are unsuitable for curative surgery or radiotherapy.
3. Tumor tissue samples have been confirmed by a central laboratory to harbor EGFR sensitive mutations (exon 19 deletion or exon 21 L858R mutation).

Project 3: A Randomized, Open-Label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of YK-029A Tablets versus Platinum-Containing Dual-Drug Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations.

Selection criteria:

1. Male or female, aged 18–75 years.  

2. Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, who have not received prior systemic anti-tumor therapy.  

The above criteria serve as primary screening guidelines. Final eligibility for enrollment will be determined by the investigator in accordance with the study protocol.

If you are interested in learning more details about this clinical study and the study drug, you can consult the following attending doctors

Contact Information

Xi Caixia: 18793598580  

Tao Wenxue: 15095632720  

Liu Xuemei: 13893522577  

Zhang Haihui: 18219858151  

Zhang Wenjing: 18093572637  

Kong Qinchao: 13884549974  

Zhang Wenbo: 18893707558

Contact address

Doctor's Office, 5th Floor, Inpatient Department, Central Campus, Room 309, Outpatient Department, Gansu Wuwei Cancer Hospital.

Department Introduction

The Second Department of Respiratory and Critical Care Medicine at Gansu Wuwei Cancer Hospital is a provincial-level key discipline integrating clinical practice, teaching, and scientific research. It is recognized as a National PCCM (Pulmonary and Critical Care Medicine) Level III Hospital Qualified Unit and serves as the Lung Cancer Early Diagnosis and Treatment Center and Pulmonary Nodule Early Diagnosis and Treatment Center under the China Lung Cancer Alliance. The department currently has a medical team of 20 members, including 1 Chief Physician, 1 Associate Chief Physician, 1 Associate Chief Nurse, 3 Attending Physicians, and 2 Resident Physicians, among whom 2 hold master's degrees. The department is responsible for clinical tasks in wards, outpatient services, and respiratory endoscopy, and has implemented multiple advanced diagnostic and therapeutic technologies. Its overall level of diagnosis and treatment is at the forefront in the province and is considered advanced nationally.

Scope of Diagnosis and Treatment: Chronic bronchitis, pulmonary infections, chronic obstructive pulmonary disease (COPD), chronic pulmonary heart disease, bronchial asthma, bronchiectasis, pulmonary embolism, pneumothorax, pleural effusion, respiratory failure, hemoptysis, malignant lung tumors, etc.  

Advanced Technologies: Painless electronic bronchoscopy, endobronchial ultrasound (EBUS)-guided diagnosis and treatment, rigid bronchoscopy, medical thoracoscopy, CT-guided biopsy, radiofrequency ablation, radioactive seed implantation, genetic testing and molecular diagnostics, artificial intelligence (AI)-assisted analysis of pulmonary nodules, etc.  

Address:

- Outpatient: Room 309, Second Department of Respiratory and Critical Care Medicine, Central Campus of Gansu Wuwei Academy of Medical and Science

- Inpatient: 5th Floor, Inpatient Building, Central Campus

Outpatient Department: 0935-6988532

Inpatient Department: 0935-6988606